IDEAYA Biosciences, Inc. (IDYA) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/11/26
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/05/26
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal MelanomaPRNewsWire • 12/11/25
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung CancersPRNewsWire • 12/10/25
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND ClearanceBusiness Wire • 12/05/25
IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptSeeking Alpha • 12/02/25
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor TypesPRNewsWire • 12/01/25
Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks AwaySeeking Alpha • 11/25/25
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations EventsPRNewsWire • 11/24/25
IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2025 SMID Cap Biopharma Call Series TranscriptSeeking Alpha • 11/07/25
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business UpdatePRNewsWire • 11/04/25
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations EventsPRNewsWire • 10/27/25
IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025PRNewsWire • 10/20/25
IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research CongressPRNewsWire • 10/20/25
IDEAYA Biosciences: Positive Darovasertib Data In Neo-Adjuvant Melanoma Sets Next CatalystSeeking Alpha • 09/08/25
IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial CancerPRNewsWire • 09/08/25
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal MelanomaPRNewsWire • 09/08/25
IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung CancerPRNewsWire • 09/07/25
IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung CancerPRNewsWire • 09/04/25
IDEAYA Biosciences, Inc. (IDYA) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeeking Alpha • 09/04/25
IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid TumorsPRNewsWire • 09/03/25
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients WorldwidePRNewsWire • 09/02/25
IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research CongressPRNewsWire • 08/29/25